Real-world costs of autosomal dominant polycystic kidney disease in the Nordics

Show full item record



Permalink

http://hdl.handle.net/10138/224201

Citation

Eriksson , D , Karlsson , L , Eklund , O , Dieperink , H , Honkanen , E , Melin , J , Selvig , K & Lundberg , J 2017 , ' Real-world costs of autosomal dominant polycystic kidney disease in the Nordics ' , BMC Health Services Research , vol. 17 , 560 . https://doi.org/10.1186/s12913-017-2513-8

Title: Real-world costs of autosomal dominant polycystic kidney disease in the Nordics
Author: Eriksson, Daniel; Karlsson, Linda; Eklund, Oskar; Dieperink, Hans; Honkanen, Eero; Melin, Jan; Selvig, Kristian; Lundberg, Johan
Contributor: University of Helsinki, Department of Medicine
Date: 2017-08-15
Language: eng
Number of pages: 9
Belongs to series: BMC Health Services Research
ISSN: 1472-6963
URI: http://hdl.handle.net/10138/224201
Abstract: Background: There is limited real-world data on the economic burden of patients with autosomal dominant polycystic kidney disease (ADPKD). The objective of this study was to estimate the annual direct and indirect costs of patients with ADPKD by severity of the disease: chronic kidney disease (CKD) stages 1-3; CKD stages 4-5; transplant recipients; and maintenance dialysis patients. Methods: A retrospective study of ADPKD patients was undertaken April-December 2014 in Denmark, Finland, Norway and Sweden. Data on medical resource utilisation were extracted from medical charts and patients were asked to complete a self-administered questionnaire. Results: A total of 266 patients were contacted, 243 (91%) of whom provided consent to participate in the study. Results showed that the economic burden of ADPKD was substantial at all levels of the disease. Lost wages due to reduced productivity were large in absolute terms across all disease strata. Mean total annual costs were highest in dialysis patients, driven by maintenance dialysis care, while the use of immunosuppressants was the main cost component for transplant care. Costs were twice as high in patients with CKD stages 4-5 compared to CKD stages 1-3. Conclusions: Costs associated with ADPKD are significant and the progression of the disease is associated with an increased frequency and intensity of medical resource utilisation. Interventions that can slow the progression of the disease have the potential to lead to substantial reductions in costs for the treatment of ADPKD.
Subject: Polycystic kidney diseases
ADPKD
Health Care Costs
Health Expenditures
Cost of Illness
STAGE RENAL-DISEASE
RESOURCE UTILIZATION
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s12913_017_2513_8.pdf 432.5Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record